Neurocrine Biosciences Announces Regulatory Approval of Dysval® (valbenazine) for the Treatment of Tardive Dyskinesia in Japan

SAN DIEGO, March 28, 2022 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its collaboration partner, Mitsubishi Tanabe Pharma Corporation (MTPC), obtained regulatory approval of DYSVAL® capsules 40 mg (valbenazine) for the treatment of tardive dyskinesia…

Click here to view original post